Courtesy of Benzinga.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced
that it has signed a definitive agreement with Allergan plc (NYSE: AGN)
to acquire Allergan Generics in a transaction valued at $40.5 billion.
Upon closing, Allergan will receive $33.75 billion in cash and shares of
Teva valued today at $6.75 billion, representing an estimated under 10%
ownership stake in Teva, with the number of Teva shares determined based
on Teva’s volume weighted average trading prices during the 15 days
prior to the announcement and five days following the announcement. Teva
believes the acquisition will be significantly accretive to non-GAAP
EPS, including expected double-digit non-GAAP EPS accretion in 2016 and
more than 20% accretion in year two and year three following the close
of the
